KPR-5714, a Novel Transient Receptor Potential Melastatin 8 Antagonist, Improves Overactive Bladder via Inhibition of Bladder Afferent Hyperactivity in Rats
- PMID: 32102918
- DOI: 10.1124/jpet.119.263616
KPR-5714, a Novel Transient Receptor Potential Melastatin 8 Antagonist, Improves Overactive Bladder via Inhibition of Bladder Afferent Hyperactivity in Rats
Abstract
Transient receptor potential (TRP) melastatin 8 (TRPM8) is a temperature-sensing ion channel mainly expressed in primary sensory neurons (Aδ-fibers and C-fibers in the dorsal root ganglion). In this report, we characterized KPR-5714 (N-[(R)-3,3-difluoro-4-hydroxy-1-(2H-1,2,3-triazol-2-yl)butan-2-yl]-3-fluoro-2-[5-(4-fluorophenyl)-1H-pyrazol-3-yl]benzamide), a novel and selective TRPM8 antagonist, to assess its therapeutic potential against frequent urination in rat models with overactive bladder (OAB). In calcium influx assays with HEK293T cells transiently expressing various TRP channels, KPR-5714 showed a potent TRPM8 antagonistic effect and high selectivity against other TRP channels. Intravenously administered KPR-5714 inhibited the hyperactivity of mechanosensitive C-fibers of bladder afferents and dose-dependently increased the intercontraction interval shortened by intravesical instillation of acetic acid in anesthetized rats. Furthermore, we examined the effects of KPR-5714 on voiding behavior in conscious rats with cerebral infarction and in those exposed to cold in metabolic cage experiments. Cerebral infarction and cold exposure induced a significant decrease in the mean voided volume and increase in voiding frequency in rats. Orally administered KPR-5714 dose-dependently increased the mean voided volume and decreased voiding frequency without affecting total voided volume in these models. This study demonstrates that KPR-5714 improves OAB in three different models by inhibiting exaggerated activity of mechanosensitive bladder C-fibers and suggests that KPR-5714 may provide a new and useful approach to the treatment of OAB. SIGNIFICANCE STATEMENT: TRPM8 is involved in bladder sensory transduction and plays a role in the abnormal activation in hypersensitive bladder disorders. KPR-5714, as a novel and selective TRPM8 antagonist, may provide a useful treatment for the disorders related to the hyperactivity of bladder afferent nerves, particularly in overactive bladder.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.
Similar articles
-
The TRPM8 channel as a potential therapeutic target for bladder hypersensitive disorders.J Smooth Muscle Res. 2022;58(0):11-21. doi: 10.1540/jsmr.58.11. J Smooth Muscle Res. 2022. PMID: 35354708 Free PMC article. Review.
-
KPR-2579, a novel TRPM8 antagonist, inhibits acetic acid-induced bladder afferent hyperactivity in rats.Neurourol Urodyn. 2018 Jun;37(5):1633-1640. doi: 10.1002/nau.23532. Epub 2018 Feb 21. Neurourol Urodyn. 2018. PMID: 29464762
-
Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β3-adrenoceptor agonist or anticholinergic agent on bladder dysfunction in rats with bladder overactivity.Eur J Pharmacol. 2021 May 15;899:173995. doi: 10.1016/j.ejphar.2021.173995. Epub 2021 Mar 3. Eur J Pharmacol. 2021. PMID: 33675781
-
KPR-5714, a selective transient receptor potential melastatin 8 antagonist, improves voiding dysfunction in rats with bladder overactivity but does not affect voiding behavior in normal rats.Neurourol Urodyn. 2022 Aug;41(6):1336-1343. doi: 10.1002/nau.24951. Epub 2022 May 10. Neurourol Urodyn. 2022. PMID: 35537073
-
The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder.BJU Int. 2010 Oct;106(8):1114-27. doi: 10.1111/j.1464-410X.2010.09650.x. BJU Int. 2010. PMID: 21156013 Review.
Cited by
-
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases.Signal Transduct Target Ther. 2023 Jul 5;8(1):261. doi: 10.1038/s41392-023-01464-x. Signal Transduct Target Ther. 2023. PMID: 37402746 Free PMC article. Review.
-
TRPM8 Channels: Advances in Structural Studies and Pharmacological Modulation.Int J Mol Sci. 2021 Aug 7;22(16):8502. doi: 10.3390/ijms22168502. Int J Mol Sci. 2021. PMID: 34445208 Free PMC article. Review.
-
Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review.Curr Ther Res Clin Exp. 2022 Apr 6;96:100669. doi: 10.1016/j.curtheres.2022.100669. eCollection 2022. Curr Ther Res Clin Exp. 2022. PMID: 35494662 Free PMC article. Review.
-
Exploration of TRPM8 Binding Sites by β-Carboline-Based Antagonists and Their In Vitro Characterization and In Vivo Analgesic Activities.J Med Chem. 2020 Sep 10;63(17):9672-9694. doi: 10.1021/acs.jmedchem.0c00816. Epub 2020 Aug 18. J Med Chem. 2020. PMID: 32787109 Free PMC article.
-
The TRPM8 channel as a potential therapeutic target for bladder hypersensitive disorders.J Smooth Muscle Res. 2022;58(0):11-21. doi: 10.1540/jsmr.58.11. J Smooth Muscle Res. 2022. PMID: 35354708 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases